Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 11, 2009Multaq(R) (dronedarone) significantly reduced the risk of cardiovascular hospitalization or death by 24 percent in patients with atrial fibrillation
-
Feb 5, 2009Team Type 1 Expands Its Roster, Fielding Five Teams to Spread Personal Messages of Successful Diabetes Management to People Living with Type 1 and Type 2 Diabetes
-
Feb 3, 2009"KidCare Kit" offers quick-reference materials and multimedia tools to guide families through the first 30 days following a child's diagnosis
-
Jan 29, 2009Sanofi-aventis U.S. Establishes 'Diabetes National Alliance' of Healthcare Professionals to Help Meet Needs of Growing Diabetes Epidemic in U.S.
-
Jan 22, 2009The Sanofi-Aventis U.S. Community Health Partnership - It's In Our Hands - Has Been Designed To Help Improve Patient Care By Connecting Patients And Caregivers To Healthcare Resources And Services In Local Communities
-
Dec 11, 2008The Sanofi-Aventis U.S. Community Health Partnership - It’s In Our Hands - Has Been Designed To Help Improve Patient Care By Connecting Patients And Caregivers To Healthcare Resources And Services In Local Communities
-
Nov 11, 2008New post-hoc analysis from Athena Study showed that Multaq® on top of standard therapy significantly decreased the total number of hospital days by 28% in patients with atrial fibrillation or flutter